Latest Information Update: 16 Nov 2005
At a glance
- Originator Quigley Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sialorrhoea
Most Recent Events
- 09 Nov 2005 Discontinued - Phase-II for Sialorrhoea in USA (unspecified route)
- 22 Jul 2002 Phase-II clinical trials in Sialorrhoea in USA (unspecified route)